2017-03-29T12:29:33-07:00 2016-06-30 990 2015-07-01 251462312 MAGEE-WOMENS RESEARCH INSTITUTE AND FOUNDATION MAGE 4126418957 3339 Ward Street Pittsburgh PA 15213 Arthur Scully III Vice President 4126418949 2017-03-29 2015 2021-01-29 14:40:06Z Michael Annichine CEO 3339 Ward Street Pittsburgh PA 15213 69001257 0 X www.mageewomens.org X 1984 PA Magee-Womens Research Institute (MWRI), the first and largest research institute in the U.S. devoted exclusively to women's health, is a recognized leader conducting unprecedented research and advancing clinical knowledge in many areas affecting women, including: reproductive biology, breast cancer, ovarian cancer, genomics and personalized therapies, HIV immunization and prevention, fertility preservation, and pelvic floor research. Magee-Womens Research Institute is dedicated to the transformation of health research for the good of all humankind . 25 22 0 231 0 0 58771738 48885965 541808 373199 2071799 1917924 747022 734444 62132367 51911532 32933713 28738678 0 0 14277186 14208909 0 0 814635 14922243 13113335 62133142 56060922 -775 -4149390 100005983 92483980 49856841 47958056 50149142 44525924 X The Board approved mission of MWRIF is to advance scientific knowledge in the fields of reproductive biology and medicine; translate this knowledge into improved health for women and infants; train current and future scholars of reproductive sciences; and foster community investment and involvement in women's health. 0 0 50326198 28738678 1235780 See Schedule O 0 0 0 50326198 1 1 0 0 0 0 0 0 0 1 1 1 0 0 1 0 1 0 0 0 1 1 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 46 0 0 0 0 0 0 0 1 1 0 0 0 0 X 25 22 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 0 1 0 0 CA CT DC FL GA MA MD NJ NY PA VA X Lisa Ascencio Director of Finance 4126418957 3339 Ward Street Pittsburgh PA 15213 Theresa Bone Director 1 0 X 0 0 0 Andrew Carey-Jaja Director 1 0 X 0 0 0 Leslie Davis Director 1 0 X 0 0 0 Robert Edwards Director 2 0 X 0 0 0 Joan Ellenbogen Director 1 0 X 0 0 0 Laura Ellsworth Director 1 0 X 0 0 0 Margaret Joy Director 2.5 0 X 0 0 0 Karen Kelley Director 1 0 X 0 0 0 Joan Snyder Kuhl Director 1 0 X 0 0 0 Ed Lettieri Director 1 0 X 0 0 0 Arthur Levine Director 1 0 X 0 0 0 Susan McGalla Director 1 0 X 0 0 0 Linda S Melada Director 1 0 X 0 0 0 William Pietragallo Director 1 0 X 0 0 0 K Scott Roy Director 1 0 X 0 0 0 W Scott Sanford Director 1 0 X 0 0 0 Patricia Siger Director 1 0 X 0 0 0 David Spigelmyer Director 1 0 X 0 0 0 Jason Harrison Treasurer 2.5 0 X X 0 0 0 Peggy Snavely Secretary 1 0 X X 0 0 0 Carrie Coghill President (effective 01/01/2016) 1 0 X X 0 0 0 Kelly R Gray Vice Chair 1 0 X X 0 0 0 David Kaplan President (Through 12/31/2015) 1 0 X X 0 0 0 Michael Annichine CEO (effective 04/11/2016) 40 0 X X 0 0 0 Yoel Sadovsky Executive Director/Professor 92 0 X X 553942 0 67113 Arthur Scully III Vice President 40 0 X X 191881 0 39628 Gerald Schatten Professor 40 0 X 309853 0 43333 Sharon Hillier Professor 40 0 X 304694 0 40759 Ian McGowan Professor 40 0 X 272800 0 36775 Elizabeth Krans Assistant Professor 40 0 X 171513 0 30381 Kyle Orwig Associate Professor 40 0 X 196176 0 28025 2000859 0 286014 45 0 1 1 University of Pittsburgh Office of Research Cost Accounting 3109 Cathedral of Learning Pittsburgh PA 15251 Medical Research 8653929 Medical Research Council Post Box 19070 Cape Town SF Medical Research 2500995 UZ-UCSF Colaborative Univ of Zimbabwe/Univ of California Initiative Belgravia Harare ZI Medical Research 2233525 Fred Hutchinson Cancer Research Center 1100 Fairview N Seattle WA 98109 Medical Research 2103822 Family Health International Post Box 602146 Charlotte NC 28260 Medical Research 1706581 27 X 63350 0 245231 0 41289864 7287520 280983 48885965 Service Fee Revenue 541380 355389 355389 0 0 Student Intern program stipend recovery 541712 17810 17810 0 0 0 0 0 0 373199 921271 0 0 921271 0 0 0 0 0 0 0 0 862581 0 0 0 862581 0 862581 862581 0 0 17843730 0 16847077 0 996653 0 996653 0 0 996653 114511 245231 242648 -128137 0 -128137 0 51911532 1235780 0 1789787 20328986 20328986 0 0 8409692 8409692 0 0 540152 65221 474931 0 0 0 0 0 10856310 8436021 2216480 203809 0 0 0 0 2812447 2237366 510419 64662 0 0 0 0 23696 23696 82928 82928 0 0 295217 295217 1410905 289020 676603 445282 5700 5700 448865 288419 68209 92237 213376 61760 122020 29596 3272702 3053675 219027 1122853 1010693 41053 71107 406789 406789 1928128 1857275 70208 645 Lab Equipment & Maintenance 917463 917463 0 0 Medical Research Supplies 1680519 1680519 0 0 Lab Testing and Processing Fees 592511 592511 0 0 Fundraising Expenses included in Part VIII -242648 0 0 -242648 954331 690788 119298 144245 56060922 50326198 4920089 814635 0 4826884 1677336 10671968 9932504 89837 177992 0 0 0 0 627450 558497 50975475 18405885 34343049 32569590 49446795 47568061 100005983 92483980 3552895 4673719 4520303 3807261 11614989 10074670 30139363 29358117 29291 44289 49856841 47958056 X 11755532 7678556 20331390 18680712 18062220 18166656 50149142 44525924 100005983 92483980 -4149390 -1752384 278556 0 0 0 X 0 1 X 1 1 1 X 50279791 50556469 45725654 58771737 48885965 254219616 0 0 0 0 0 0 0 0 50279791 50556469 45725654 58771737 48885965 254219616 11385335 242834281 2008360 1976447 1719011 1597092 1783852 9084762 0 0 0 0 0 0 0 0 263304378 2999298 0.92226 0.93603 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 22878830 873005 -58413 0 3546422 0 20147000 22336456 860738 316392 0 634756 0 22878830 20383708 11625 2506831 0 565708 0 22336456 18959728 56904 1897654 0 530578 0 20383708 19328380 18850 -6643 0 380859 0 18959728 0.091 0.901 0.008 1 0 0 0 0 0 44437642 12977415 31460227 0 931198 727923 203275 0 5606635 4700547 906088 0 0 0 0 32569590 0 0 Money Market 5969469 F Fixed Income 6519461 F Domestic Equity 19246256 F International Equity 7522954 F Alternative Investments 7373902 F Beneficial Interest in Trust 936019 F 47568061 0 Agency funds held for womens Auxillary 44289 44289 50428417 -1752384 321838 0 0 -1430546 51858963 295217 -242648 52569 51911532 56051635 43282 0 0 242648 285930 55765705 295217 0 295217 56060922 Schedule D, Part V, Line 4 Endowments are used to carry out the mission of the organization, i.e., to conduct medical research related to women's health and to support the operations of Magee Womens Hospital. Schedule D, Part XI, Line 4b Fundraising expenses of $242,648 netted against revenue on 990 but included in expenses in audited Financial Statements. Schedule D, Part XII, Line 2d $242,648 reconciling item represents fundraising expenses included in expense section of audited financials but reported as a revenue offset in Part VIII line 8 of 990. 1 Sub-Saharan Africa 0 0 Grantmaking 8247870 Europe (including Iceland and Greenland) 0 0 Grantmaking 90032 East Asia and the Pacific 0 0 Grantmaking 41790 South America 0 0 Grantmaking 30000 0 0 8409692 South America To conduct clinical trials of microbicides for the prevention of HIV 30000 Wire Transfer 0 Sub-Saharan Africa To conduct clinical trials of microbicides for the prevention of HIV 323430 Wire Transfer 0 Sub-Saharan Africa To conduct clinical trials of microbicides for the prevention of HIV 1204772 Wire Transfer 0 East Asia and the Pacific To conduct clinical trials of microbicides for the prevention of HIV 41790 Wire Transfer 0 Sub-Saharan Africa To conduct clinical trials of microbicides for the prevention of HIV 10800 Wire Transfer 0 Sub-Saharan Africa To conduct clinical trials of microbicides for the prevention of HIV 958381 Wire Transfer 0 Sub-Saharan Africa To conduct clinical trials of microbicides for the prevention of HIV 2500995 Wire Transfer 0 Sub-Saharan Africa To conduct clinical trials of microbicides for the prevention of HIV 414111 Wire Transfer 0 Europe (including Iceland and Greenland) Characterization of meosis 90032 Wire Transfer 0 Sub-Saharan Africa To conduct clinical trials of microbicides for the prevention of HIV 2233525 Wire Transfer 0 Sub-Saharan Africa To conduct clinical trials of microbicides for the prevention of HIV 601856 Wire Transfer 0 11 0 0 0 0 0 0 0 Schedule F, Part I, Line 2 All grants & assistance to foreign organizations relate to collaborative biomedical research with the organizations. Each arrangement is formalized with a contract which includes specific terms & conditions that must be met. Each recipient is required to submit a detailed accounting of all expenditures incurred under the contract. This is reviewed for contract compliance and appropriateness, and only then is cash transferred to them under the grant agreement as a reimbursement. Each recipient organization is also required to submit annual reports of all research activities funded by the grant and the results of the research. This information is reviewed by the U.S. scientist who is leading the research. Savor Pittsburgh 220175 132399 87776 0 4706 20545 15385 3000 70344 Fly fishing 68500 53333 15167 0 0 15000 0 0 5724 5 64468 54400 10068 0 0 13267 14868 0 4824 353143 240132 113011 0 4706 48812 30253 3000 80892 167663 -54652 1 Magee Womens Hospital of UPMC 300 Halket Street Pittsburgh PA 15213 250965420 501(c)(3) 475566 0 Contribution for Hospital Activities Brown University Cashiers office Box 1911 Providence RI 02912 050258809 501(c)(3) 16017 0 Biomedical Research Carnegie Mellon University Po Box 371032 Pittsburgh PA 15250 250969449 501(c)(3) 205594 0 Biomedical Research Case Western University 10900 Euclid Avenue Cleveland OH 44106 341018992 501(c)(3) 24423 0 Biomedical Research National Foundation for Center for Disease Control & Prevention 55 park Place suite 400 Atlanta GA 30303 582106707 501(c)(3) 142496 0 Biomedical Research New York University 70 Washington Square south New York NY 10012 135562308 501(c)(3) 177510 0 Biomedical Research Pennsylvania State University 227 W Beaver avenue Suite 401 State College PA 16801 246000376 501(c)(3) 27835 0 Biomedical Research Population Council One Dag Hammarskjold Plaza New York NY 10017 131687001 501(c)(3) 195854 0 Biomedical Research Public Health Foundation enterprises 12801 Crossroads Pkwy S City of Industry CA 91746 952557063 501(c)(3) 454556 0 Biomedical Research Regents of the University of Michigan 500 S State St Ann Arbor MI 48109 386006309 501(c)(3) 175844 0 Biomedical Research Research foundation for Mental Hygiene 150 Broadway Menands NY 12204 141410842 501(c)(3) 318394 0 biomedical Research Research Triangle Institute 5265 Capital Boulevard Raleigh NC 27616 560686338 501(c)(3) 819097 0 Biomedical Research San Francisco Department of Public Health 1380 Howard Street San Francisco CA 94103 000000000 501(c)(3) 57358 0 Biomedical Research Research Foundation for the State University of New York PO Box 9 Albany NY 12201 141368361 501(c)(3) 68899 0 Biomedical Research Tulane University 800 East Commerce Road Harahan LA 70123 720423889 501(c)(3) 24020 0 Biomedical Research University of Texas One UTSA Circle San Antonio TX 78249 746000089 501(c)(3) 406313 0 Biomedical Research University of California Los Angeles 405 Hilgard Avenue Los Angeles CA 90095 956006143 501(c)(3) 94668 0 Biomedical Research The Regent of the University of California at Davis 1850 Research Park Drive suite 300 Davis CA 95618 946036494 501(c)(3) 28207 0 Biomedical Research University of Alabama 1720 second Avenue South Birmingham AL 35294 636005396 501(c)(3) 311430 0 Biomedical Research University of California San Diego 9500 Gilman Avenue La Jolla CA 92093 956006144 501(c)(3) 372447 0 Biomedical Research University of Colorado Denver 1775 Aurora Court Denver CO 80045 846000555 501(c)(3) 172319 0 Biomedical Research University of North Carolina at Chapel Hill 104 Airport Dr Chapel Hill NC 27599 566001393 501(c)(3) 711121 0 Biomedical Research University of Pittsburgh 4200 fifth Avenue Pittsburgh PA 15260 250965591 501(c)(3) 8653929 0 Biomedical Research University of Washington Gerberding Hall G80 Seattle WA 98195 916001537 501(c)(3) 924505 0 Biomedical Research Columbia University 116th street and Broadway New York NY 10027 135598093 501(c)(3) 29916 0 Biomedical Research Eastern Virginia Medical School 700 W Olney Road Norfolk VA 23507 546055378 501(c)(3) 15802 0 Biomedical Research Yeshiva University 1300 Morris Park avenue Bronx NY 10461 237075620 501(c)(3) 107324 0 Biomedical Research Emory University 954 Gatewood Road Atlanta GA 30329 580566256 501(c)(3) 20370 0 Biomedical Research Family Health International 359 Blackwell Street Durham NC 27701 237413005 501(c)(3) 1706581 0 Biomedical Research Fred Hutchinson Cancer research Center 1100 Fairview Avenue N Seattle WA 98109 237156071 501(c)(3) 2103822 0 Biomedical Research John Hopkins University 733 North Broadway Baltimore MD 21218 520595110 501(c)(3) 1486768 0 Biomedical Research 31 0 Schedule I, Part I, Line 2 Each recipient of grant funding enters into a contract with MWRIF. The contract details allowable uses of funds and includes a detailed budget listing anticipated expenditures. Funds are released to recipients on a cost reimbursement basis. The recipient submits a report summarizing the expenditure incurred, which is carefully reviewed by MWRIF personnel against budgets and terms of the contract before funds are released. X 1 1 X 0 0 0 0 0 0 0 1 0 Yoel Sadovsky Executive Director/Professor 450387 0 100953 0 2602 0 47830 0 19283 0 621055 0 0 Arthur Scully III Vice President 191281 0 0 0 600 0 23530 0 16098 0 231509 0 0 Gerald Schatten Professor 309252 0 0 0 600 0 31801 0 11533 0 353186 0 0 0 Sharon Hillier Professor 253744 0 50000 0 950 0 30450 0 10309 0 345453 0 0 0 Ian McGowan Professor 222200 0 50000 0 600 0 32220 0 4555 0 309575 0 0 Elizabeth Krans Assistant Professor 171000 0 0 0 513 0 20520 0 9861 0 201894 0 0 0 Kyle Orwig Associate Professor 195576 0 0 0 600 0 23470 0 4555 0 224201 0 0 0 Schedule J, Part I, Line 1a Membership dues for the Duquesne Club, a private club located in Pittsburgh's downtown business district, are paid by MWRIF for Arthur Scully, VP of Development. The Club's facility is used to host Board and Donor meetings and related events. Schedule J, Part I, Line 3 The Executive Director is dually employed by both the University of Pittsburgh and the University of Pittsburgh Medical Center (UPMC). 100% of his time is spent on either his biomedical research or his Executive Director responsibilities, so MWRIF is financially responsible for his total compensation. Each of the three organizations are involved in evaluating the ED's compensation taking into account accomplishments, responsibilities, and comparison to AAMC (American Association of Medical Colleges) benchmarks. The initial salary as well as subsequent adjustments must be approved by senior management of the University and UPMC, and is also approved by select independent directors of MWRIF board. A written employment contract is used by both employers to document all employment terms including compensation. All paperwork regarding the process and approvals is maintained by the respective organizations. Schedule J, Part I, Line 7 In addition to a base compensation from each employer, Dr. Sadovsky is eligible for incentive compensation as follows: From UPMC, he is eligible for performance based incentive compensation as part of his employment contract. Performance is evaluated against a list of predetermined goals and payment is made in the subsequent fiscal year. From the University of Pittsburgh, he is eligible for a research incentive based on certain criteria established by the University for all researchers. This is tied to his own research lab and is not related to his function as Executive Director of MWRIF. Gerald Schatten, Sharon Hillier, Ian McGowan, Elizabeth Krans, and Kyle Orwig are also eligible for the University of Pittsburgh research incentive mentioned above, if they meet the criteria established by the University. Schedule J, Part II (Also 990 Part VII, Section A): MICHAEL ANNICHINE joined the Organization as its CEO effective 04/11/2016. Since compensation information disclosed in this Form 990 Part VII and Schedule J relates to compensation paid out for the Calendar Year 2015, there is no reportable compensation for Mr. Annichine. ELIZABETH KRANS is dually employed by both the University of Pittsburgh and the University of Pittsburgh Medical Center (UPMC). She divides her time between clinical work and her research pursuits. The reportable wages shown on Schedule J Part II and Part VII Line 1a represent the portion of her combined salary attributable to her research work which is the responsibility of MWRIF. UPMC is responsible for the portion of her combined salary attributable to her clinical work. X 4706 Retail value X 11 262907 FMV X Food served at Events 7 13370 FMV 0 0 1 1 Schedule M, Part I, Line 32b Registered stock brokers are used to sell stock contributions. Stock is sold immediately upon receipt. Form 990, Part I, Line 5 MWRIF doesn't have any employees of its own. All individuals who work in support of the mission of MWRIF are employed either by the University of Pittsburgh or the University of Pittsburgh Medical Center (UPMC). MWRIF is billed by each organization for the cost of salary and fringe benefits corresponding to the effort these individuals expend in support of the MWRIF mission. MWRIF records such costs as compensation on its financial statements. Payroll taxes are filed by the employer organizations. Form 990, Part III, Line 4a Magee-Womens Research Institute (MWRI), the first and largest research institute in the U.S. devoted exclusively to women's health, is a recognized leader conducting unprecedented research and advancing clinical knowledge in many areas affecting women, including: reproductive biology, breast cancer, ovarian cancer, genomics and personalized therapies, HIV immunization and prevention, fertility preservation, and pelvic floor research. Magee-Womens Research Institute is dedicated to the transformation of health research for the good of all humankind. Though women comprise 50% of the population, they give birth to 100% of future generations. As researchers, this fact has led us to the realization that women's health is the key to human wellness. Remarkable for its potential to revolutionize the art and science of medicine, this insight is the foundation of the Magee Movement. By embracing this new perspective, we will develop pragmatic solutions and prevent problems once considered inevitable. We envision a future in which all physicians and researchers routinely address the genetic and gestational causes of chronic and devastating developments like diabetes and cardiovascular disease in an attempt to prevent their occurrence. We believe that our best defense against infectious disease is to empower women. We are dedicated to fostering wellness by incorporating gender-based medicine. These tenets have motivated us to refocus our research in to three pillars: PILLAR 1: 9-90: From conception onward, the first nine months of pregnancy contain the key to many of life's questions about health and well-being. Through our 9-90TM research, scientists investigate how the 9 months of pregnancy impact the next 90 years of life. The nine months in utero are so universally important because the moment of greatest plasticity - or the ability to be easily shaped or molded - is during pregnancy. It is during this time that factors such as environmental exposure, nutrition, and infection, as well as other influences, most greatly impact fetal development and leave a lasting mark. Studying this "human blueprint" allows scientists to better predict the conditions that will affect a person later in life and potentially change or cure those conditions. Areas of study in 9-90 are: REPRODUCTIVE DEVELOPMENT: Uncovering the mechanisms that underlie genetic abnormalities is crucial to reducing birth defects and improving the health of infants. PREGNANCY & NEWBORNS: A healthy start in life is the key to a lifetime of well-being. Magee scientists continue to make lifesaving discoveries about key diseases such as preeclampsia, fetal growth abnormalities, preterm birth, prenatal genetics and the lifelong impact stemming from these diseases through research spanning fetal development, pregnancy and pregnancy outcomes that shape maternal and neonatal health. REPRODUCTIVE PHYSIOLOGY & FERTILITY: Infertility is heartbreaking to the couple who desperately wants a child to love. Our scientists study the fundamental mechanisms that govern germ cell biology and complex pathways that lead to human infertility, to discover means for restoring fertility to diverse populations including young cancer survivors. GENETICS: Genetic studies of placental development are furthering medical science's understanding of how hormonal, nutritional and environmental signals in the womb influence genes that regulate all aspects of our physiology. PILLAR 2: GENDER SPECIFIC MEDICINE (GSM): For hundreds of years, scientists have been studying human disease processes while employing male research subjects almost exclusively. This approach has established a baseline for understanding, but truly effective human health research demands the study of both female and male responses to disease origin, prevention, and treatment. The differences between women and men and the distinctive ways they present with disease, respond to treatment, and recover can tell us much about how to ensure each patient receives the right treatment in the right way at the right time. Areas of study in GSM are: WOMENS CANCERS: At Magee, our response to Cancer is to find new and better ways to prevent and treat it. With recent breakthroughs in genomic discovery, we now have the tools to identify biomarkers for cancer risk, severity and prognosis. Through large scale clinical trials performed as a part of the national consortia, Magee scientists and physicians investigate ovarian and other pelvic cancers, examine the causes, prevention and treatment of breast cancer, and assess the impact cancer has on a woman's quality of life. UROGYNECOLOGY: We are unyielding in our determination to find ways to improve patient care in the treatment of the female pelvic floor. We are set on finding better treatments for conditions that affect women of reproductive age through maturity. WOMENS HEALTH & WELLNESS: An appalling one in four women will experience domestic abuse in her lifetime. Specific areas of focus include intimate partner violence, teen pregnancy, prenatal care and postpartum depression. We also pinpoint gaps in the quality of health and healthcare across racial, ethnic and socioeconomic groups that result in higher incidence of chronic diseases, higher mortality and poorer health outcomes for women. PILLAR 3: INFECTIOUS DISEASES: Magee is focusing its efforts on the global threat of infectious diseases and our clinical trials are yielding breakthrough results all over the world. Our organization receives more HIV&AIDS research funding from the NIH than any other research center in the country - and, in 2006, the NIH established the Microbicide Trials Network (MTN) at Magee-Womens Research Institute. Led by Sharon Hillier, PhD, the MTN is a worldwide collaborative clinical trials network focused on preventing the transmission of HIV. Today, eleven years later, the MTN operates more than 20 sites in Africa, Southeast Asia and the United States. Form 990, Part VI, Section A, Line 2 Directors Arthur Levine and Linda Melada have a family relationship. Form 990, Part VI, Section B, Line 11b The initial draft of the Form 990, which is prepared by the Accounting Manager, is reviewed by the Director of Finance. It is then reviewed externally by representative of MWRIF's external auditors Maher Duessel. After that, the Audit Committee, a sub-committee of the Board of Directors, reviews and provides a report to the Board. A copy of the Form 990 is provided to the full Board of Directors prior to filing with the IRS. Form 990, Part VI, Section B, Line 12c The organization has a conflict of interest policy that is driven by the classification of each individual as follows: Board members are required to sign a formal conflict of interest questionnaire annually prior to the beginning of each fiscal year for which they are a member. The forms are reviewed internally by the VP of Development and Communications and actual or potential conflicts are reported to the Board Chair. * Designated individuals (managers and above, and any employee holding a position of influence or trust) supporting MWRIF who are employed by UPMC are required to follow their employer mandated conflict of interest policy which includes annual electronic disclosures, as well as additional disclosures as related circumstances change. These are reviewed and monitored by the UPMC Ethics and Compliance Committee. If potential and actual conflicts are identified, a Conflict Management Plan must be developed and submitted to the Committee. Failure to disclose potential conflicts or to follow the approved conflict management plan will result in disciplinary action. * Designated individuals (all faculty, staff with administrator IV title or above and any others designated based on their responsibilities) working at MWRIF who are employees of the University of Pittsburgh are required to follow their employer mandated conflict of interest policy which includes annual electronic conflict of interest disclosures, as well as additional disclosures as related circumstances change. These are reviewed by the individual's department head and reported to University senior management as well as maintained by the Conflict of Interest Committee. Potential or actual conflicts are handled by the employees first line supervisor and a management plan developed. The plan is submitted to senior management as well as the COI committee for review. Sanctions may be applied for non-compliance with the requirements of the policy or with management plans, including a letter of reprimand, special monitoring of future work, removal from the particular project, probation, suspension, salary reduction, or initiation of steps leading to possible reduction in rank or termination of employment. Form 990, Part VI, Section B, Line 15 The Executive Director is dually employed by both University of Pittsburgh and the University of Pittsburgh Medical Center (UPMC). 100% of his time is spent on either his medical research (about 46 hours/week average) or on his Executive Director responsibilities (an additional 46 hours/week average), for an average total of 92 hours per week. MWRIF is financially responsible for his total compensation and it reimburses the University of Pittsburgh and UPMC for his compensation. Each of the three organizations are involved in evaluating the ED's compensation taking into consideration his accomplishments, responsibilities, and comparing against AAMC (American Association of Medical Colleges) benchmarks. The initial salary as well as any subsequent adjustments are approved by senior management of the University and UPMC and by selected external members of the MWRIF Board. All paperwork regarding the process and approvals is maintained by the respective organizations. Form 990, Part VI, Section C, Line 19 The Conflict of Interest Policy, governing documents, and financial statements are available at the Organization's business office located at 3339 Ward street, Pittsburgh, PA 15213. Form 990, Part VIII, Line 6a The research conducted at MWRIF occurs in a facility located at 204 Craft Avenue. UPMC owns this building and MWRIF is renting the space from them. Since the lease agreement with UPMC is long term (30 years), for accounting purposes it has to be recorded as a liability on MWRIF's books. This is the mortgage/note payable disclosed on Line 24 of Part X. The lease agreement does not contain any terms implying that MWRIF will ever own or have the option to buy the building. The rental income disclosed in Part VIII is generated by subleases between MWRIF and several research labs that are part of the University of Pittsburgh, allowing them to occupy a portion of the space MWRIF is renting from UPMC. These particular University of Pittsburgh researchers collaborate with MWRIF researchers on a regular basis on large biomedical research projects where physical proximity facilitates the collaborative process and allows them to meet, share equipment and other resources as needed to make the collaboration more efficient and hopefully more successful. The objective in renting the space to the University of Pittsburgh is to facilitate the collaboration, not to generate profit. So the rental income disclosed in Part VIII is sublease income that offsets a portion of MWRIF's lease expense. MWRIF has no acquisition indebtedness which would require the rental income to be disclosed as unrelated business income.